Long-term Outcome of Intravitreal Triamcinolone Acetonide injection for the Treatment of Uveitis Attacks in Behçet Disease

References

• Tugal-tutkun I, Onal S, Altan-Yaycioglu R, et al. Uveitis in Behçet's disease: an analysis of 880 patients. Am J Ophthalmol. 2004;138:373–380
   PubMed Web of Science ®Google Scholar
• Deuter CM, Kötter I, Wallace GR, et al. Behçet's disease: ocular effects and treatment. Prog Retin Eye Res. 2008;27:111–136
   PubMed Web of Science ®Google Scholar
• Okada AA. Drug therapy in Behçet's disease. Ocul Immunol Inflamm. 2000;8:85–91
   PubMed Web of Science ®Google Scholar
• Thomas ER, Wang J, Ege E, et al. Intravitreal triamcinolone acetonide concentration after subtenon injection. Am J Ophthalmol. 2006;142:860–861
   PubMed Web of Science ®Google Scholar
• Gillies MC, McAllister IL, Zhu M, et al. Intravitreal triamcinolone prior to laser treatment of diabetic macular edema: 24-month results of a randomized controlled trial. Ophthalmology. 2011;118:866–872
   PubMed Web of Science ®Google Scholar
• Ding X, Li J, Hu X, et al. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion. Retina. 2011;31:838–845
   PubMedGoogle Scholar
• Gillies MC, Larsson J. The effect of intravitreal triamcinolone on foveal edema in exudative macular degeneration. Am J Ophthalmol. 2007;144:134–136
   PubMedGoogle Scholar
• Kok H, Lau C, Maycock N, et al. Outcome of intravitreal triamcinolone in uveitis. Ophthalmology. 2005;112:1916.e1–e7
   PubMed Web of Science ®Google Scholar
• International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet. 1990;335:1078–1080
   PubMed Web of Science ®Google Scholar
• Nussenblatt RB, Palestine AG, Chan CC, et al. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985;92:467–471
   PubMed Web of Science ®Google Scholar
• Benzon HT, Chew TL, McCarthy RJ, et al. Comparison of the particle sizes of different steroids and the effect of dilution: a review of the relative neurotoxicities of the steroids. Anesthesiology. 2007;106:331–338
   PubMed Web of Science ®Google Scholar
• Kiernan DF, Mieler WF. The use of intraocular corticosteroids. Expert Opin Pharmacother. 2009;10:2511–2525
   PubMed Web of Science ®Google Scholar
• Adigüzel U, Sari A, Ozmen C, et al. Intravitreal triamcinolone acetonide treatment for serpiginous choroiditis. Ocul Immunol Inflamm. 2006;14:375–378
   PubMed Web of Science ®Google Scholar
• Jonas JB, Spandau UH. Repeated intravitreal triamcinolone acetonide for chronic sympathetic ophthalmia. Acta Ophthalmol Scand. 2006;84:436
   PubMedGoogle Scholar
• Chan WM, Lim E, Liu DT, et al. Intravitreal triamcinolone acetonide for choroidal granuloma in sarcoidosis. Am J Ophthalmol. 2005;139:1116–1118
   PubMedGoogle Scholar
• Shah A, Branley M. Use of intravitreal triamcinolone in the management of birdshot retinochoroidopathy associated with cystoid macular oedema: a case study over a three-year period. Clin Exp Ophthalmol. 2005;33:442–444
   PubMed Web of Science ®Google Scholar
• Byon IS, Kim JH, Lee JE, et al. Intravitreal triamcinolone acetonide for rebound phenomenon after high-dose intravenous steroid treatment in Vogt-Koyanagi-Harada disease. Clin Ophthalmol. 2011;5:1589–1591
   PubMedGoogle Scholar
• Ozkiris A. Intravitreal triamcinolone acetonide injection for the treatment of posterior uveitis. Ocul Immunol Inflamm. 2006;14:233–238
   PubMed Web of Science ®Google Scholar
• Tuncer S, Yilmaz S, Urgancioglu M, et al. Results of intravitreal triamcinolone acetonide (IVTA) injection for the treatment of panuveitis attacks in patients with Behçet disease. J Ocul Pharmacol Ther. 2007;23:395–401
   PubMed Web of Science ®Google Scholar
• Nguyen QD, Ibrahim MA, Watters A, et al. Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE study. J Ophthalmic Inflamm Infect. 2013;3:32
   PubMedGoogle Scholar
• Kim SJ, Doherty TJ, Cherney EF. Intravitreal ketorolac for chronic uveitis and macular edema: a pilot study. Arch Ophthalmol. 2012;130:456–460
   PubMedGoogle Scholar
• Bae JH, Lee SC. Effect of intravitreal methotrexate and aqueous humor cytokines levels in refractory retinal vasculitis in Behçet disease. Retina. 2012;32:1395–1402
   PubMed Web of Science ®Google Scholar
• Okhravi N, Lightman S. Cystoid macular edema in uveitis. Ocul Immunol Inflamm. 2003;11:29–38
   PubMed Web of Science ®Google Scholar
• Atmaca LS, Yalçindağ FN. Ozdemir O. Intravitreal triamcinolong acetonide in the management of cystoid macular edema in Behçet's disease. Graefes Arch Clin Exp Ophthalmol. 2007;245:451–456
   PubMed Web of Science ®Google Scholar
• Karacorlu M, Mudun B, Ozdemir H, et al. Intravitreal triamcinolone acetonide for the treatment of cystoid macular edema secondary to Behcet disease. Am J Ophthalmol. 2004;138:289–291
   PubMed Web of Science ®Google Scholar
• Sallam A, Comer RM, Chang JH, et al. Short-term safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema in children. Arch Ophthalmol. 2008;126:200–205
   PubMed Web of Science ®Google Scholar
• Bae JH, Lee CS, Lee SC. Efficacy and safety of intravitreal bevacizumab compared with intravitreal and posterior sub-Tenon triamcinolone acetonide for treatment of uveitic cystoid macular edema. Retina. 2011;31:111–118
   PubMed Web of Science ®Google Scholar
• Androudi S, Letko E, Meniconi M, et al. Safety and efficacy of intravitreal triamcinolone acetonide for uveitic macular edema. Ocul Immunol Inflamm. 2005;13:205–212
   PubMed Web of Science ®Google Scholar
• Antcliff RJ, Spalton DJ, Stanford MR, et al. Intravitreal triamcinolone for uveitic cystoids macular edema: an optical coherence tomography study. Ophthalmology. 2001;108:765–772
   PubMed Web of Science ®Google Scholar
• Young S, Larkin G, Branley M, et al. Safety and efficacy of intravitreal triamcinolone for cystoids macular oedema in uveitis. Clin Exp Ophthalmol. 2001;29:2–6
   PubMed Web of Science ®Google Scholar
• Galor A, Margolis R, Brasil OM, et al. Adverse events after intravitreal triamcinolone in patients with and without uveitis. Ophthalmology. 2007;114:1912–1918
   PubMed Web of Science ®Google Scholar
• Ohguro N, Yamanaka E, Otori Y, et al. Repeated intravitreal triamcinolone injections in Behçet disease that is resistant to conventional therapy: one-year results. Am J Ophthalmol. 2006;141:218–220
   PubMed Web of Science ®Google Scholar
• Sallam A, Taylor SR, Habot-Wilner Z, et al. Repeat intravitreal triamcinolone acetonide injections in uveitic macular oedema. Acta Ophthalmol. 2012;90:e323–e325
   PubMed Web of Science ®Google Scholar
• Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol. 2003;87:24–27
   PubMed Web of Science ®Google Scholar
• Park UC, Kim SJ, Yu HG. Cytomegalovirus endotheliitis after fluocinolone acetonide (Retisert) implant in a patient with Behçet's uveitis. Ocul Immunol Inflamm. 2011;19:282–283
   PubMed Web of Science ®Google Scholar
• Cordero-Coma M, Yilmaz T, Onal S. Systemic review of anti-tumor necrosis factor-alpha therapy for treatment of immune-mediated uveitis. Ocul Immunol Inflamm. 2013;21:12–20
   Web of Science ®Google Scholar
• Mesquida M, Victoria Hernández M, et al. Behçet disease-associated uveitis successfully treated with golimumab. Ocul Immunol Inflamm. 2013;21:160–162
   PubMed Web of Science ®Google Scholar